Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence

ABSTRACT Reversible tardive dyskinesia (TD) outcomes have been reported in long-term neuroleptic (NL)-treated patients. In this study the course of TD outcomes was followed-up for 3 years in

a population of 125 institutionalized schizophrenic patients (mean age 57.8 years) receiving continuous NL treatment. Tardive dyskinesia occurrence and severity were assessed by means of

the Rockland Simpson Scale (RSS). The prevalence of TD rose from 39.2% at the first examination to 52.8% at last follow-up examination; however, 28.6% of TD-affected patients recovered and

30% improved. Significant risk factors for a persistent TD outcome result included age over 56 years, duration of illness over 30 years, and a total RSS score over 22. Cumulative NL

exposure, over 3550 g of chloropromazine equivalents, was also a significant risk factor for TD. Results from this study confirm that there is the possibility of improvement and remission in

an aged, long-term institutionalized population of TD patients. In this report we point out prognostic factors for positive outcome. SIMILAR CONTENT BEING VIEWED BY OTHERS EFFICACY AND

ACCEPTABILITY OF PHARMACOLOGICAL INTERVENTIONS FOR TARDIVE DYSKINESIA IN PEOPLE WITH SCHIZOPHRENIA OR MOOD DISORDERS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS Article 18 December 2024

LONG-TERM EFFECT OF APOMORPHINE INFUSION IN ADVANCED PARKINSON’S DISEASE: A REAL-LIFE STUDY Article Open access 11 June 2021 A RANDOMIZED CONTROLLED DOUBLE-BLIND STUDY OF ROTIGOTINE ON

NEUROPSYCHIATRIC SYMPTOMS IN DE NOVO PD Article Open access 15 December 2020 ARTICLE PDF AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * From the Department of Neuropsychiatric Sciences, S.

Raffaele Hospital, University of Milan, Italy Roberto Cavallaro M.D., Maria Grazia Regazzetti M.D., Emanuela Mundo M.D., Viviana Brancato M.D. & Enrico Smeraldi M.D. Authors * Roberto

Cavallaro M.D. View author publications You can also search for this author inPubMed Google Scholar * Maria Grazia Regazzetti M.D. View author publications You can also search for this

author inPubMed Google Scholar * Emanuela Mundo M.D. View author publications You can also search for this author inPubMed Google Scholar * Viviana Brancato M.D. View author publications You

can also search for this author inPubMed Google Scholar * Enrico Smeraldi M.D. View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS

Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Cavallaro, R., Regazzetti, M., Mundo, E. _et al._ Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of

Remission and Persistence. _Neuropsychopharmacol_ 8, 233–239 (1993). https://doi.org/10.1038/npp.1993.26 Download citation * Received: 27 November 1991 * Revised: 03 August 1992 * Accepted:

10 August 1992 * Issue Date: 01 May 1993 * DOI: https://doi.org/10.1038/npp.1993.26 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get

shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS *

Drug-induced dyskinesia * Schizophrenia * Prognosis * Risk factors * Tranquilizing agents * Age